Affluent Medical has appointed Howard Herrmann (Perelman School of Medicine at the University of Pennsylvania, Philadelphia, USA) as strategic chief medical officer (CMO) for its structural heart platform.
The appointment underscores the company’s commitment to enhancing clinical expertise and driving innovation as it advances its Kaliostm mitral ring and Epygon mitral valve, Affluent Medical says in a press release.
Herrmann is professor of medicine at the Perelman School of Medicine at the University of Pennsylvania and director of interventional cardiology at the Hospital of the University of Pennsylvania, Philadelphia.
He has over three decades of experience in transcatheter device therapies for valvular and structural heart diseases, and has authored over 500 publications and served as president of the Pennsylvania chapter of the American College of Cardiology (ACC).
Additionally, Affluent Medical has named Federica Azzimonti as director of clinical operations to lead the operational aspects of Affluent Medical clinical trials, ensuring streamlined execution as the company prepares for pivotal stages.
Nicolas Barry Delongchamps (Cochin Hospital, Paris Descartes University, Paris, France) has also been named as chief medical officer for Affluent’s urology platform.
“These appointments come at a crucial time as we enter our next phase of growth, transitioning into pivotal phases and continuing to progress towards commercialization of our devices.” said Sébastien Ladet, CEO of Affluent Medical. “The addition of strong medical experts has been a deliberate move that demonstrates Affluent Medical commitment to execute and to offer the best available therapies worldwide.”
The company has also recently announced that it has coopted Liane Teplitsky as a new Board member. Recently appointed CEO of Artedrone, an autonomous robotic solution for mechanical thrombectomy, Teplitsky was most recently president, Global Robotics, Technology & Data Solutions at Zimmer Biomet where she led the global growth and development of the company’s portfolio of robotics and digital health technologies, having also held roles at Abbott and St Jude Medical.
